Press Release - January 13, 2014
Sernova to Present Company and Clinical Update at Biotech Showcase™ Healthcare Conference in San Francisco
LONDON, ONTARIO--(Marketwire – Jan. 13, 2014) - Sernova Corp (TSX-V:
SVA), today announced that Dr. Philip Toleikis, Ph.D., the company’s Chief
Executive Officer will present an update on the company’s business
strategy and clinical study at the Biotech Showcase(TM) healthcare
conference in San Francisco, CA. This important conference brings together
global industry leaders, emerging companies and members of the
investment community. Sernova is currently conducting a Phase I/II clinical
trial of its Cell Pouch(TM) at the University of Alberta in patients with Type 1
diabetes who are receiving an islet transplant with Dr. James Shapiro as
Details of Sernova Corp’s presentation are as follows: Event: Biotech Showcase(TM) 2014 Conference Date: January 14, 2014 Time: 4:30 P.M. PST Location: Parc 55 Wyndham SF Union Sq. Hotel; 3(rd) Floor Track D Powell
“We are presenting Sernova’s strategic approach and product development advancements during the industry’s largest conglomerate of annual healthcare investor conferences and arguably the most important healthcare investment symposia in the industry,” remarked Dr. Philip Toleikis, President and CEO.
“With Sernova anticipating the release of Phase I/II interim clinical efficacy data in 2014, as well as advancements in our other programs and collaborations, this is an excellent opportunity to highlight the company’s progress and future direction,” added Dr. Toleikis.
About the Biotech Showcase(TM) (Innovation –Opportunity – Collaboration)
Co-produced by Demy-Colton Life Science Advisors and EBD Group, Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry’s largest annual healthcare investor conferences. Now in its sixth year, Biotech Showcase is expected to attract upwards of 1,500 attendees.
Sernova Corp is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including haemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device for therapeutic cells (donor, xenogeneic or stem cells) which then release proteins and/or hormones as required. The therapeutic cells are protected from immune attack by Sernova’s proprietary technology, Sertolin(TM).
About the Cell Pouch(TM)
The Cell Pouch(TM) is a proprietary scalable biocompatible medical device, contract manufactured (ISO13485) to meet international regulatory standards. It is inserted under the skin, and forms an ideal environment, rich in microvessels and tissue matrix for the placement and function of therapeutic cells. The Cell Pouch(TM) is currently being evaluated in clinical trials at the University of Alberta with Dr. James Shapiro as principal investigator in patients with Type 1 diabetes receiving an islet transplant.
Sertoli cells when co-localized with donor therapeutic cells release protective factors that can provide a non-toxic, immune-protected environment that may reduce or eliminate the need for daily anti-rejection drugs that currently must be used by patients with transplanted tissues and organs. Sernova is currently conducting preclinical studies to optimize sertoli cells and islets within the Cell Pouch(TM) through a NRC-IRAP contribution agreement provided by the Government of Canada.
About Clinical Islet Transplantation Program
Please view www.islet@ca for more information on the Clinical Islet Transplantation Program at the University of Alberta. For further information contact:
Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 email@example.com www.sernova.com
Ray Matthews and Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 www.raymatthews.ca 604.818.7778
Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Press Releases from:2018 2017 2016 2015 2014 2013 2012
2011 2010 2009 2008 2007 2006 2005
2004 2003 2002 2001 2000 1999
2014, January 22
Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare CostsLink
2012, July 11
Sernova Corp. developing a tiered approach to the treatment of diabetes
Publisher: Canadian Investor Magazine
Author: Rochelle Emnance
2012, July 30
Feds back local diabetes discovery
Publisher: London Free Press
Author: Norman De Bono
2012, July 30
Federal program pumps $3 million into new, London business
Publisher: The London Free Press
Author: Norman De Bono
2010 July 10
Canada's economic action plan supports business innovators
Publisher: Federal Economic Development Agency for Southern OntarioLink
2007, February 20
"Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"
Author: Julie Ickes and James Finch
2006, October 04
"Sertoli Cells: Mother nature's anti-rejection drug"
Author: James Finch
2006, August 24
"Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"
Author: James Finch
Presentation and Video
May 03, 2018
March 29, 2018
2018 Financial Report - 1st Quarter
March 29, 2018
2018 Management Discussion & Analysis (MD&A) - 1st Quarter
December 11, 2017
Clearance by FDA of Sernova's US IND
Conference call audio recording
September 11, 2017
Sernova Fact Sheet
Subscribe to Sernova News
All Updates →